دورية أكاديمية
Initiatives to challenge patent barriers and their relationship with the price of medicines procured by the Brazilian Unified National Health System.
| العنوان: | Initiatives to challenge patent barriers and their relationship with the price of medicines procured by the Brazilian Unified National Health System. |
|---|---|
| عنوان ترانسليتريتد: | Iniciativas de enfrentamento da barreira patentária e a relação com o preço de medicamentos adquiridos pelo Sistema Único de Saúde. |
| المؤلفون: | Scopel CT; Escola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil., Chaves GC; Escola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil. |
| المصدر: | Cadernos de saude publica [Cad Saude Publica] 2016 Dec 01; Vol. 32 (11), pp. e00113815. Date of Electronic Publication: 2016 Dec 01. |
| نوع المنشور: | Journal Article |
| اللغة: | Portuguese; English |
| بيانات الدورية: | Publisher: Escola Nacional De Saúde Pública, Fundação Oswaldo Cruz Country of Publication: Brazil NLM ID: 8901573 Publication Model: Electronic Cited Medium: Internet ISSN: 1678-4464 (Electronic) Linking ISSN: 0102311X NLM ISO Abbreviation: Cad Saude Publica Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2012->: Rio De Janeiro : Escola Nacional De Saúde Pública, Fundação Oswaldo Cruz Original Publication: Rio de Janeiro : A Escola, |
| مواضيع طبية MeSH: | Anti-HIV Agents/*economics , Drug Costs/*statistics & numerical data , Lopinavir/*economics , Patents as Topic/*legislation & jurisprudence , Ritonavir/*economics, Anti-HIV Agents/supply & distribution ; Brazil ; Drug Costs/legislation & jurisprudence ; Government Programs ; HIV Infections/drug therapy ; Humans ; Longitudinal Studies ; Lopinavir/supply & distribution ; Ritonavir/supply & distribution |
| مستخلص: | Since 1996, when antiretroviral (ARV) treatments started being guaranteed to people living with HIV in Brazil, the government has faced the challenge of ensuring sustainability of this policy within a context of incorporating patented medicines. This article sought to analyze the historical series of the price of lopinavir/ritonavir (LPV/r) in Brazil and in the international market also considering the initiatives to challenge patent barriers between 2001 and 2012. The methods used were mapping initiatives to challenge LPV/r patent barriers and the analysis of historical series of its price in Brazil and in the international market. Results show that, between 2001 and 2003, there were efforts to use compulsory licensing as a threat. From 2005 to 2007, initiatives by different satkeholders were identified: declaration of public interest, pre-grant opposition ("support to examination") and civil action. From 2006 to 2008, compulsory licensing initiatives in other countries resulted in a price reduction in Brazil. Between 2009 and 2012, there was a 30% reduction in the Brazilian purchasing price. |
| المشرفين على المادة: | 0 (Anti-HIV Agents) 2494G1JF75 (Lopinavir) O3J8G9O825 (Ritonavir) |
| تواريخ الأحداث: | Date Created: 20161208 Date Completed: 20170503 Latest Revision: 20170817 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1590/0102-311X00113815 |
| PMID: | 27925025 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1678-4464 |
|---|---|
| DOI: | 10.1590/0102-311X00113815 |